Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
Age
6–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject who completed the C87035 study (NCT00899678) through Week 62 or assessments when their participation in C87035 was terminated when the study was stopped by UBC
Subject completed all assessments required for Week 62/Visit 23 at the time of termination
Subjects maintain stable regimen of concomitant medications for Crohn's Disease (CD) throughout study
You may not be if
Subject who did not complete the C87035 study (Week 62 Visit), was terminated or did not complete all of the Week 62 assessments when their participation from C87035 was terminated when the study was stopped by UCB but did not complete all assessments required for Week 62/Visit 23 at the time of termination
Clareo Health | Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
